Windtree Therapeutics, Inc. (WINT) 10-Year Financial Performance & Capital Metrics

WINT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesCardiovascular Therapeutics

AboutWindtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.Show more

Revenue $0
EBITDA -$25M -42.8%
Net Income -$5M +73.0%
EPS (Diluted) -104.35 +97.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -81.98% +72.9%
ROIC -144.67% -21.1%
Debt/Equity 0.18 -96.3%
Interest Coverage -106.46 +69.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-320.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.09%

ROCE

10Y Avg-85.91%

5Y Avg-69.53%

3Y Avg-77.43%

Latest-98.95%

Peer Comparison

Cardiovascular Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
WINTWindtree Therapeutics, Inc.	674.18K	0.02	-0.00		-453.96%	-4539.56%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	987K	2.04M	1.49M	1.79M	198K	0	0	0	0	0
Revenue Growth %	-0.65%	1.07%	-0.27%	0.2%	-0.89%	-1%	-	-	-	-
Cost of Goods Sold+	929K	255K	17.38M	10.56M	12.69K	638K	869K	1.06M	82K	84K
COGS % of Revenue	0.94%	0.12%	11.7%	5.91%	0.06%	-	-	-	-	-
Gross Profit+	58K	1.79M	-15.89M	-8.77M	185.31K	-638K	-869K	-1.06M	-82K	-84K
Gross Margin %	0.06%	0.88%	-10.7%	-4.91%	0.94%	-	-	-	-	-
Gross Profit Growth %	-0.65%	29.81%	-9.89%	0.45%	1.02%	-4.44%	-0.36%	-0.22%	0.92%	-0.02%
Operating Expenses+	39.89M	40.08M	24.03M	17.98M	25.09M	30.32M	31.39M	20.43M	17.46M	24.93M
OpEx % of Revenue	40.42%	19.63%	16.18%	10.06%	126.72%	-	-	-	-	-
Selling, General & Admin	11M	8.37M	6.66M	7.42M	12.4M	14.94M	14.47M	10.79M	9.2M	8.74M
SG&A % of Revenue	11.15%	4.1%	4.48%	4.15%	62.65%	-	-	-	-	-
Research & Development	28.89M	31.7M	17.38M	10.56M	12.69M	15.37M	17.79M	11.1M	8.26M	16.28M
R&D % of Revenue	29.27%	15.53%	11.7%	5.91%	64.08%	-	-	-	-	-
Other Operating Expenses	0	0	129K	401K	0	0	-869K	-1.46M	0	-84K
Operating Income+	-39.83M	-38.04M	-22.55M	-16.2M	-24.89M	-30.32M	-77.28M	-41.33M	-17.54M	-25.02M
Operating Margin %	-40.36%	-18.63%	-15.18%	-9.06%	-125.72%	-	-	-	-	-
Operating Income Growth %	0.08%	0.05%	0.41%	0.28%	-0.54%	-0.22%	-1.55%	0.47%	0.58%	-0.43%
EBITDA+	-39.12M	-37.78M	-22.36M	-16.04M	-23.78M	-29.68M	-76.41M	-40.27M	-17.46M	-24.93M
EBITDA Margin %	-39.64%	-18.5%	-15.05%	-8.97%	-120.11%	-	-	-	-	-
EBITDA Growth %	0.08%	0.03%	0.41%	0.28%	-0.48%	-0.25%	-1.57%	0.47%	0.57%	-0.43%
D&A (Non-Cash Add-back)	712K	255K	192K	159K	1.11M	638K	869K	1.06M	82K	84K
EBIT	-50.59M	-36.97M	-16.58M	-19.12M	-26.98M	-32.44M	-77.51M	-40.52M	-20.24M	-1.56M
Net Interest Income+	-4.58M	-2.5M	-1.85M	-1.39M	-342K	-3K	-23K	56K	275K	-165K
Interest Income	4K	18K	12K	15K	153K	122K	91K	109K	325K	70K
Interest Expense	4.58M	2.52M	1.86M	1.41M	495K	125K	114K	53K	50K	235K
Other Income/Expense	-15.34M	-1.45M	4.1M	-4.34M	-2.58M	-2.25M	-45.36M	758K	-2.75M	23.23M
Pretax Income+	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-32.57M	-77.62M	-40.58M	-20.29M	-1.79M
Pretax Margin %	-55.9%	-19.34%	-12.42%	-11.48%	-138.76%	-	-	-	-	-
Income Tax+	0	0	0	0	0	-2.29M	-9.99M	-1.37M	0	3.69M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.93%	0.87%	0.97%	1%	3.06%
Net Income+	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-30.28M	-67.64M	-39.21M	-20.29M	-5.49M
Net Margin %	-55.9%	-19.34%	-12.42%	-11.48%	-138.76%	-	-	-	-	-
Net Income Growth %	-0.25%	0.28%	0.53%	-0.11%	-0.34%	-0.1%	-1.23%	0.42%	0.48%	0.73%
Net Income (Continuing)	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-30.28M	-67.64M	-39.21M	-20.29M	-5.49M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-113138.00	-93616.00	-122924.00	-56011.00	-4711.54	-104.35
EPS Growth %	-0.09%	0.4%	0.75%	0.68%	0.89%	0.17%	-0.31%	0.54%	0.92%	0.98%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-113138.00	-93616.00	-122924.00	-56011.00	-4711.54	-104.35
Diluted Shares Outstanding	3	3	8	33	243	348	550	700	4.31K	52.58K
Basic Shares Outstanding	3	3	8	33	243	348	550	700	4.31K	52.58K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	40.79M	7.19M	2.24M	25.65M	23.86M	18.12M	23.49M	7.38M	5.38M	2.57M
Cash & Short-Term Investments	38.72M	5.59M	1.81M	25.15M	22.58M	16.93M	22.35M	6.17M	4.32M	1.78M
Cash Only	38.72M	5.59M	1.81M	11.19M	22.58M	16.93M	22.35M	6.17M	4.32M	1.78M
Short-Term Investments	0	0	0	13.96M	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.07M	1.61M	422K	507K	0	1.19M	0	1.21M	1.06M	795K
Total Non-Current Assets+	3.58M	2.5M	1.11M	93.75M	95.11M	94.77M	51.3M	30.58M	27.03M	25.3M
Property, Plant & Equipment	1.04M	1.05M	885K	802K	2.19M	1.84M	3.39M	2.12M	1.63M	1.16M
Fixed Asset Turnover	0.95x	1.94x	1.68x	2.23x	0.09x	-	-	-	-	-
Goodwill	0	0	0	15.68M	15.68M	15.68M	15.68M	3.06M	0	0
Intangible Assets	0	0	0	77.09M	77.09M	77.09M	32.07M	25.25M	25.25M	24.13M
Long-Term Investments	225K	225K	225K	171K	154K	0	154K	154K	150K	9K
Other Non-Current Assets	2.32M	1.23M	0	-195.98M	154K	154K	154K	154K	0	0
Total Assets+	44.38M	9.7M	3.35M	119.4M	118.97M	112.89M	74.79M	37.95M	32.41M	27.88M
Asset Turnover	0.02x	0.21x	0.44x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	-0.07%	-0.78%	-0.65%	34.67%	-0%	-0.05%	-0.34%	-0.49%	-0.15%	-0.14%
Total Current Liabilities+	11.07M	13.39M	11.76M	20.63M	7.82M	6.13M	4.92M	2.46M	4M	5.72M
Accounts Payable	3.26M	1.81M	3.05M	3.42M	1.71M	1.16M	693K	249K	809K	1.88M
Days Payables Outstanding	1.28K	2.6K	64.03	118.19	49.14K	664.21	291.08	85.66	3.6K	8.16K
Short-Term Debt	0	0	0	7.97M	161K	352K	294K	252K	233K	661K
Deferred Revenue (Current)	0	0	884K	198K	0	0	0	0	0	0
Other Current Liabilities	5.03M	10.27M	6.82M	5.65M	4.5M	2.6M	2.19M	0	900K	963K
Current Ratio	3.69x	0.54x	0.19x	1.24x	3.05x	2.96x	4.77x	3.00x	1.35x	0.45x
Quick Ratio	3.69x	0.54x	0.19x	1.24x	3.05x	2.96x	4.77x	3.00x	1.35x	0.45x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	25.04M	25.14M	15.51M	30.65M	36.22M	37.2M	27.98M	25.48M	25.02M	12.16M
Long-Term Debt	25M	25M	15M	15M	4.61M	2.42M	15M	0	15M	0
Capital Lease Obligations	0	0	0	0	794K	201K	2.07M	1.62M	1.16M	653K
Deferred Tax Liabilities	0	0	-15M	15.48M	15.82M	16.78M	7.11M	5.06M	5.06M	4.53M
Other Non-Current Liabilities	43K	138K	100K	175K	15M	17.8M	3.8M	18.8M	3.8M	6.98M
Total Liabilities	36.11M	38.53M	27.27M	51.28M	44.04M	43.33M	32.91M	27.94M	29.02M	17.88M
Total Debt+	25M	25M	15M	7.97M	6.31M	3.78M	17.89M	2.28M	16.83M	1.82M
Net Debt	-13.72M	19.41M	13.19M	-3.21M	-16.27M	-13.15M	-19.45M	-3.89M	12.51M	43K
Debt / Equity	3.02x	-	-	0.12x	0.08x	0.05x	0.43x	0.23x	4.96x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.69x	-15.11x	-12.10x	-11.49x	-50.29x	-242.54x	-677.89x	-779.87x	-350.78x	-106.46x
Total Equity+	8.27M	-28.83M	-23.92M	68.11M	74.94M	69.55M	41.88M	10.01M	3.39M	10M
Equity Growth %	-0.57%	-4.49%	0.17%	3.85%	0.1%	-0.07%	-0.4%	-0.76%	-0.66%	1.95%
Book Value per Share	999999.00	-999999.00	-999999.00	999999.00	308572.02	199938.67	76116.52	14302.86	787.51	190.10
Total Shareholders' Equity	8.27M	-28.83M	-23.92M	68.11M	74.94M	69.55M	41.88M	10.01M	3.39M	10M
Common Stock	8K	9K	3K	32K	41K	17K	28K	0	0	0
Retained Earnings	-579.18M	-618.67M	-637.11M	-657.65M	-685.12M	-717.69M	-785.32M	-824.53M	-844.82M	-846.61M
Treasury Stock	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M
Accumulated OCI	-8.47M	-6.96M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.5M	-33.59M	-21.05M	-15.78M	-24.66M	-25.32M	-23.66M	-19.45M	-13.44M	-15.4M
Operating CF Margin %	-33.95%	-16.45%	-14.17%	-8.83%	-124.56%	-	-	-	-	-
Operating CF Growth %	0.19%	-0%	0.37%	0.25%	-0.56%	-0.03%	0.07%	0.18%	0.31%	-0.15%
Net Income	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-32.57M	-67.64M	-39.21M	-20.29M	-1.79M
Depreciation & Amortization	712K	255K	192K	159K	195K	165K	192K	533K	82K	84K
Stock-Based Compensation	2.23M	1.69M	1.66M	955K	6.72M	5.68M	7.24M	3.09M	1.28M	455K
Deferred Taxes	10.14M	-1.7M	0	3.34M	1.72M	1.14M	-9.99M	-1.37M	0	-210K
Other Non-Cash Items	3.64M	3.17M	-4.91M	863K	882K	1.59M	46.59M	19.28M	3.48M	-15.31M
Working Capital Changes	4.94M	2.49M	466K	-562K	-6.71M	-1.33M	-58K	-1.78M	2.02M	1.37M
Change in Receivables	1.93M	0	0	0	0	0	0	0	0	0
Change in Inventory	201K	0	0	0	0	0	0	0	0	0
Change in Payables	2.91M	1.44M	2.43M	997K	-2.47M	-547K	-468K	-444K	560K	1.07M
Cash from Investing+	-188K	-254K	-24K	-13.73M	13.8M	-291K	-279K	197K	-15K	-12K
Capital Expenditures	-458K	-281K	-24K	0	-191K	-291K	-279K	-13K	-15K	-12K
CapEx % of Revenue	0.46%	0.14%	0.02%	-	0.96%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	270K	27K	0	9K	0	0	0	0	0	0
Cash from Financing+	27.7M	709K	17.3M	38.74M	21.77M	19.96M	29.36M	3.08M	11.6M	12.73M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-657K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	27.57M	709K	-2.5M	-155K	-1.21M	2.94M	5.84M	0	843K	8.52M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-33.96M	-33.87M	-21.07M	-15.78M	-24.85M	-25.61M	-23.94M	-19.46M	-13.45M	-15.41M
FCF Margin %	-34.41%	-16.59%	-14.19%	-8.83%	-125.53%	-	-	-	-	-
FCF Growth %	0.19%	0%	0.38%	0.25%	-0.57%	-0.03%	0.06%	0.19%	0.31%	-0.15%
FCF per Share	-999999.00	-999999.00	-999999.00	-474167.62	-102345.35	-73608.66	-43515.15	-27807.14	-3124.01	-293.14
FCF Conversion (FCF/Net Income)	0.61x	0.85x	1.14x	0.77x	0.90x	0.84x	0.35x	0.50x	0.66x	2.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-401.75%	-	-	-92.92%	-38.41%	-41.91%	-121.39%	-151.11%	-302.78%	-81.98%
Return on Invested Capital (ROIC)	-	-	-	-44.85%	-30.22%	-39.52%	-123.54%	-142.38%	-119.46%	-144.67%
Gross Margin	5.88%	87.51%	-1070.1%	-490.72%	93.59%	-	-	-	-	-
Net Margin	-5589.67%	-1933.89%	-1242.15%	-1148.38%	-13876.26%	-	-	-	-	-
Debt / Equity	3.02x	-	-	0.12x	0.08x	0.05x	0.43x	0.23x	4.96x	0.18x
Interest Coverage	-8.69x	-15.11x	-12.10x	-11.49x	-50.29x	-242.54x	-677.89x	-779.87x	-350.78x	-106.46x
FCF Conversion	0.61x	0.85x	1.14x	0.77x	0.90x	0.84x	0.35x	0.50x	0.66x	2.81x
Revenue Growth	-65.19%	106.89%	-27.28%	20.4%	-88.93%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Windtree Therapeutics, Inc. (WINT) reported $0.1M in revenue for fiscal year 2024. This represents a 85% decrease from $0.6M in 2011.

Windtree Therapeutics, Inc. (WINT) grew revenue by 0.0% over the past year. Growth has been modest.

Windtree Therapeutics, Inc. (WINT) reported a net loss of $40.9M for fiscal year 2024.

Dividend & Returns

Yes, Windtree Therapeutics, Inc. (WINT) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Windtree Therapeutics, Inc. (WINT) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.

Windtree Therapeutics, Inc. (WINT) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Windtree Therapeutics, Inc. (WINT) 10-Year Financial Performance & Capital Metrics

WINT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesCardiovascular Therapeutics

Revenue $0
EBITDA -$25M -42.8%
Net Income -$5M +73.0%
EPS (Diluted) -104.35 +97.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -81.98% +72.9%
ROIC -144.67% -21.1%
Debt/Equity 0.18 -96.3%
Interest Coverage -106.46 +69.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-320.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.09%

ROCE

10Y Avg-85.91%

5Y Avg-69.53%

3Y Avg-77.43%

Latest-98.95%

Peer Comparison

Cardiovascular Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
WINTWindtree Therapeutics, Inc.	674.18K	0.02	-0.00		-453.96%	-4539.56%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	987K	2.04M	1.49M	1.79M	198K	0	0	0	0	0
Revenue Growth %	-0.65%	1.07%	-0.27%	0.2%	-0.89%	-1%	-	-	-	-
Cost of Goods Sold+	929K	255K	17.38M	10.56M	12.69K	638K	869K	1.06M	82K	84K
COGS % of Revenue	0.94%	0.12%	11.7%	5.91%	0.06%	-	-	-	-	-
Gross Profit+	58K	1.79M	-15.89M	-8.77M	185.31K	-638K	-869K	-1.06M	-82K	-84K
Gross Margin %	0.06%	0.88%	-10.7%	-4.91%	0.94%	-	-	-	-	-
Gross Profit Growth %	-0.65%	29.81%	-9.89%	0.45%	1.02%	-4.44%	-0.36%	-0.22%	0.92%	-0.02%
Operating Expenses+	39.89M	40.08M	24.03M	17.98M	25.09M	30.32M	31.39M	20.43M	17.46M	24.93M
OpEx % of Revenue	40.42%	19.63%	16.18%	10.06%	126.72%	-	-	-	-	-
Selling, General & Admin	11M	8.37M	6.66M	7.42M	12.4M	14.94M	14.47M	10.79M	9.2M	8.74M
SG&A % of Revenue	11.15%	4.1%	4.48%	4.15%	62.65%	-	-	-	-	-
Research & Development	28.89M	31.7M	17.38M	10.56M	12.69M	15.37M	17.79M	11.1M	8.26M	16.28M
R&D % of Revenue	29.27%	15.53%	11.7%	5.91%	64.08%	-	-	-	-	-
Other Operating Expenses	0	0	129K	401K	0	0	-869K	-1.46M	0	-84K
Operating Income+	-39.83M	-38.04M	-22.55M	-16.2M	-24.89M	-30.32M	-77.28M	-41.33M	-17.54M	-25.02M
Operating Margin %	-40.36%	-18.63%	-15.18%	-9.06%	-125.72%	-	-	-	-	-
Operating Income Growth %	0.08%	0.05%	0.41%	0.28%	-0.54%	-0.22%	-1.55%	0.47%	0.58%	-0.43%
EBITDA+	-39.12M	-37.78M	-22.36M	-16.04M	-23.78M	-29.68M	-76.41M	-40.27M	-17.46M	-24.93M
EBITDA Margin %	-39.64%	-18.5%	-15.05%	-8.97%	-120.11%	-	-	-	-	-
EBITDA Growth %	0.08%	0.03%	0.41%	0.28%	-0.48%	-0.25%	-1.57%	0.47%	0.57%	-0.43%
D&A (Non-Cash Add-back)	712K	255K	192K	159K	1.11M	638K	869K	1.06M	82K	84K
EBIT	-50.59M	-36.97M	-16.58M	-19.12M	-26.98M	-32.44M	-77.51M	-40.52M	-20.24M	-1.56M
Net Interest Income+	-4.58M	-2.5M	-1.85M	-1.39M	-342K	-3K	-23K	56K	275K	-165K
Interest Income	4K	18K	12K	15K	153K	122K	91K	109K	325K	70K
Interest Expense	4.58M	2.52M	1.86M	1.41M	495K	125K	114K	53K	50K	235K
Other Income/Expense	-15.34M	-1.45M	4.1M	-4.34M	-2.58M	-2.25M	-45.36M	758K	-2.75M	23.23M
Pretax Income+	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-32.57M	-77.62M	-40.58M	-20.29M	-1.79M
Pretax Margin %	-55.9%	-19.34%	-12.42%	-11.48%	-138.76%	-	-	-	-	-
Income Tax+	0	0	0	0	0	-2.29M	-9.99M	-1.37M	0	3.69M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.93%	0.87%	0.97%	1%	3.06%
Net Income+	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-30.28M	-67.64M	-39.21M	-20.29M	-5.49M
Net Margin %	-55.9%	-19.34%	-12.42%	-11.48%	-138.76%	-	-	-	-	-
Net Income Growth %	-0.25%	0.28%	0.53%	-0.11%	-0.34%	-0.1%	-1.23%	0.42%	0.48%	0.73%
Net Income (Continuing)	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-30.28M	-67.64M	-39.21M	-20.29M	-5.49M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-113138.00	-93616.00	-122924.00	-56011.00	-4711.54	-104.35
EPS Growth %	-0.09%	0.4%	0.75%	0.68%	0.89%	0.17%	-0.31%	0.54%	0.92%	0.98%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-113138.00	-93616.00	-122924.00	-56011.00	-4711.54	-104.35
Diluted Shares Outstanding	3	3	8	33	243	348	550	700	4.31K	52.58K
Basic Shares Outstanding	3	3	8	33	243	348	550	700	4.31K	52.58K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	40.79M	7.19M	2.24M	25.65M	23.86M	18.12M	23.49M	7.38M	5.38M	2.57M
Cash & Short-Term Investments	38.72M	5.59M	1.81M	25.15M	22.58M	16.93M	22.35M	6.17M	4.32M	1.78M
Cash Only	38.72M	5.59M	1.81M	11.19M	22.58M	16.93M	22.35M	6.17M	4.32M	1.78M
Short-Term Investments	0	0	0	13.96M	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.07M	1.61M	422K	507K	0	1.19M	0	1.21M	1.06M	795K
Total Non-Current Assets+	3.58M	2.5M	1.11M	93.75M	95.11M	94.77M	51.3M	30.58M	27.03M	25.3M
Property, Plant & Equipment	1.04M	1.05M	885K	802K	2.19M	1.84M	3.39M	2.12M	1.63M	1.16M
Fixed Asset Turnover	0.95x	1.94x	1.68x	2.23x	0.09x	-	-	-	-	-
Goodwill	0	0	0	15.68M	15.68M	15.68M	15.68M	3.06M	0	0
Intangible Assets	0	0	0	77.09M	77.09M	77.09M	32.07M	25.25M	25.25M	24.13M
Long-Term Investments	225K	225K	225K	171K	154K	0	154K	154K	150K	9K
Other Non-Current Assets	2.32M	1.23M	0	-195.98M	154K	154K	154K	154K	0	0
Total Assets+	44.38M	9.7M	3.35M	119.4M	118.97M	112.89M	74.79M	37.95M	32.41M	27.88M
Asset Turnover	0.02x	0.21x	0.44x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	-0.07%	-0.78%	-0.65%	34.67%	-0%	-0.05%	-0.34%	-0.49%	-0.15%	-0.14%
Total Current Liabilities+	11.07M	13.39M	11.76M	20.63M	7.82M	6.13M	4.92M	2.46M	4M	5.72M
Accounts Payable	3.26M	1.81M	3.05M	3.42M	1.71M	1.16M	693K	249K	809K	1.88M
Days Payables Outstanding	1.28K	2.6K	64.03	118.19	49.14K	664.21	291.08	85.66	3.6K	8.16K
Short-Term Debt	0	0	0	7.97M	161K	352K	294K	252K	233K	661K
Deferred Revenue (Current)	0	0	884K	198K	0	0	0	0	0	0
Other Current Liabilities	5.03M	10.27M	6.82M	5.65M	4.5M	2.6M	2.19M	0	900K	963K
Current Ratio	3.69x	0.54x	0.19x	1.24x	3.05x	2.96x	4.77x	3.00x	1.35x	0.45x
Quick Ratio	3.69x	0.54x	0.19x	1.24x	3.05x	2.96x	4.77x	3.00x	1.35x	0.45x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	25.04M	25.14M	15.51M	30.65M	36.22M	37.2M	27.98M	25.48M	25.02M	12.16M
Long-Term Debt	25M	25M	15M	15M	4.61M	2.42M	15M	0	15M	0
Capital Lease Obligations	0	0	0	0	794K	201K	2.07M	1.62M	1.16M	653K
Deferred Tax Liabilities	0	0	-15M	15.48M	15.82M	16.78M	7.11M	5.06M	5.06M	4.53M
Other Non-Current Liabilities	43K	138K	100K	175K	15M	17.8M	3.8M	18.8M	3.8M	6.98M
Total Liabilities	36.11M	38.53M	27.27M	51.28M	44.04M	43.33M	32.91M	27.94M	29.02M	17.88M
Total Debt+	25M	25M	15M	7.97M	6.31M	3.78M	17.89M	2.28M	16.83M	1.82M
Net Debt	-13.72M	19.41M	13.19M	-3.21M	-16.27M	-13.15M	-19.45M	-3.89M	12.51M	43K
Debt / Equity	3.02x	-	-	0.12x	0.08x	0.05x	0.43x	0.23x	4.96x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.69x	-15.11x	-12.10x	-11.49x	-50.29x	-242.54x	-677.89x	-779.87x	-350.78x	-106.46x
Total Equity+	8.27M	-28.83M	-23.92M	68.11M	74.94M	69.55M	41.88M	10.01M	3.39M	10M
Equity Growth %	-0.57%	-4.49%	0.17%	3.85%	0.1%	-0.07%	-0.4%	-0.76%	-0.66%	1.95%
Book Value per Share	999999.00	-999999.00	-999999.00	999999.00	308572.02	199938.67	76116.52	14302.86	787.51	190.10
Total Shareholders' Equity	8.27M	-28.83M	-23.92M	68.11M	74.94M	69.55M	41.88M	10.01M	3.39M	10M
Common Stock	8K	9K	3K	32K	41K	17K	28K	0	0	0
Retained Earnings	-579.18M	-618.67M	-637.11M	-657.65M	-685.12M	-717.69M	-785.32M	-824.53M	-844.82M	-846.61M
Treasury Stock	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M	-3.05M
Accumulated OCI	-8.47M	-6.96M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.5M	-33.59M	-21.05M	-15.78M	-24.66M	-25.32M	-23.66M	-19.45M	-13.44M	-15.4M
Operating CF Margin %	-33.95%	-16.45%	-14.17%	-8.83%	-124.56%	-	-	-	-	-
Operating CF Growth %	0.19%	-0%	0.37%	0.25%	-0.56%	-0.03%	0.07%	0.18%	0.31%	-0.15%
Net Income	-55.17M	-39.49M	-18.45M	-20.53M	-27.48M	-32.57M	-67.64M	-39.21M	-20.29M	-1.79M
Depreciation & Amortization	712K	255K	192K	159K	195K	165K	192K	533K	82K	84K
Stock-Based Compensation	2.23M	1.69M	1.66M	955K	6.72M	5.68M	7.24M	3.09M	1.28M	455K
Deferred Taxes	10.14M	-1.7M	0	3.34M	1.72M	1.14M	-9.99M	-1.37M	0	-210K
Other Non-Cash Items	3.64M	3.17M	-4.91M	863K	882K	1.59M	46.59M	19.28M	3.48M	-15.31M
Working Capital Changes	4.94M	2.49M	466K	-562K	-6.71M	-1.33M	-58K	-1.78M	2.02M	1.37M
Change in Receivables	1.93M	0	0	0	0	0	0	0	0	0
Change in Inventory	201K	0	0	0	0	0	0	0	0	0
Change in Payables	2.91M	1.44M	2.43M	997K	-2.47M	-547K	-468K	-444K	560K	1.07M
Cash from Investing+	-188K	-254K	-24K	-13.73M	13.8M	-291K	-279K	197K	-15K	-12K
Capital Expenditures	-458K	-281K	-24K	0	-191K	-291K	-279K	-13K	-15K	-12K
CapEx % of Revenue	0.46%	0.14%	0.02%	-	0.96%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	270K	27K	0	9K	0	0	0	0	0	0
Cash from Financing+	27.7M	709K	17.3M	38.74M	21.77M	19.96M	29.36M	3.08M	11.6M	12.73M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-657K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	27.57M	709K	-2.5M	-155K	-1.21M	2.94M	5.84M	0	843K	8.52M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-33.96M	-33.87M	-21.07M	-15.78M	-24.85M	-25.61M	-23.94M	-19.46M	-13.45M	-15.41M
FCF Margin %	-34.41%	-16.59%	-14.19%	-8.83%	-125.53%	-	-	-	-	-
FCF Growth %	0.19%	0%	0.38%	0.25%	-0.57%	-0.03%	0.06%	0.19%	0.31%	-0.15%
FCF per Share	-999999.00	-999999.00	-999999.00	-474167.62	-102345.35	-73608.66	-43515.15	-27807.14	-3124.01	-293.14
FCF Conversion (FCF/Net Income)	0.61x	0.85x	1.14x	0.77x	0.90x	0.84x	0.35x	0.50x	0.66x	2.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-401.75%	-	-	-92.92%	-38.41%	-41.91%	-121.39%	-151.11%	-302.78%	-81.98%
Return on Invested Capital (ROIC)	-	-	-	-44.85%	-30.22%	-39.52%	-123.54%	-142.38%	-119.46%	-144.67%
Gross Margin	5.88%	87.51%	-1070.1%	-490.72%	93.59%	-	-	-	-	-
Net Margin	-5589.67%	-1933.89%	-1242.15%	-1148.38%	-13876.26%	-	-	-	-	-
Debt / Equity	3.02x	-	-	0.12x	0.08x	0.05x	0.43x	0.23x	4.96x	0.18x
Interest Coverage	-8.69x	-15.11x	-12.10x	-11.49x	-50.29x	-242.54x	-677.89x	-779.87x	-350.78x	-106.46x
FCF Conversion	0.61x	0.85x	1.14x	0.77x	0.90x	0.84x	0.35x	0.50x	0.66x	2.81x
Revenue Growth	-65.19%	106.89%	-27.28%	20.4%	-88.93%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Windtree Therapeutics, Inc. (WINT) reported $0.1M in revenue for fiscal year 2024. This represents a 85% decrease from $0.6M in 2011.

Windtree Therapeutics, Inc. (WINT) grew revenue by 0.0% over the past year. Growth has been modest.

Windtree Therapeutics, Inc. (WINT) reported a net loss of $40.9M for fiscal year 2024.

Dividend & Returns

Yes, Windtree Therapeutics, Inc. (WINT) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Windtree Therapeutics, Inc. (WINT) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.

Windtree Therapeutics, Inc. (WINT) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.